Fig. 2.
Risks of grade ≥3 cardiac adverse events (A and B) and overall survival (C and D) stratified by serum high-sensitivity cardiac troponin T (hs-cTnT) levels: baseline hs-cTnT levels <10 ng/L vs. ≥10 ng/L and hs-cTnT delta (peak minus baseline) during chemoradiation therapy <5 ng/L vs. ≥5 ng/L.